FGFR3 and cholangiocarcinoma: The FDA has granted approval for Infigratinib, Pemigatinib, and Futibatinib in the treatment of cholangiocarcinoma with FGFR2 fusion, as well as Erdafitinib in the treatment of bladder cancer with FGFR3 mutation.